Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$112,649 | -$116,271 | -$89,763 | -$35,761 |
| Dep. & Amort. | $799 | $604 | $123 | $83 |
| Deferred Tax | -$26,589 | $0 | $0 | $0 |
| Stock-Based Comp. | $19,918 | $19,582 | $15,016 | $2,478 |
| Change in WC | -$3,704 | $6,369 | $1,624 | $3,014 |
| Other Non-Cash | $22,182 | $682 | $1,935 | $5 |
| Operating Cash Flow | -$100,043 | -$89,034 | -$71,065 | -$30,181 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$2,719 | -$769 | -$297 |
| Net Acquisitions | -$9,133 | $4 | $34,853 | $0 |
| Inv. Purchases | -$154,719 | -$176,528 | -$247,142 | -$31,412 |
| Inv. Sales/Matur. | $264,588 | $172,417 | $67,337 | $0 |
| Other Inv. Act. | $0 | -$4 | -$34,853 | -$31 |
| Investing Cash Flow | $100,736 | -$6,830 | -$180,574 | -$31,709 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $1,325 | $0 | $0 | $253,314 |
| Stock Repurch. | $0 | $0 | $0 | -$17 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$7,808 | $1,160 | $36,237 | $350,899 |
| Financing Cash Flow | $1,325 | $1 | $36 | $350,899 |
| Forex Effect | -$6 | $1 | $0 | $0 |
| Net Chg. in Cash | $2,012 | -$94,703 | -$215,402 | $289,009 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $54,986 | $150,060 | $365,462 | $76,453 |
| End Cash | $56,998 | $55,357 | $150,060 | $365,462 |
| Free Cash Flow | -$100,043 | -$91,753 | -$71,834 | -$30,478 |